Anagnostics' Oncogene tests for personalized oncology are easy to use and deliver fast and comprehensive results. Using Anagnostics compact sequencing technology, a high number of clinically relevant mutations is targeted. The existing KRAS test is extended to test further mutations (BRAF, EGFR...).
Benefits:
• Few hands-on steps
• Fast (< 90 minutes)
• Sensitive (detection of < 1 % mutation vs. wildtype DNA)
• All clinically relevant mutations are directly identified
• Cost effective analysing 1 to 8 samples without expensive reagent wasting
Principle:
Genomic DNA from fresh tissue, fresh frozen tissue or in formaline fixed and in paraffin embedded (FFPE) tissue is used as sample material. The sequence enclosing codons (e.g. KRAS 12/13) are amplified in an upstream PCR reaction. Fluorescence-labelled PCR amplificates bind to immobilized probes on the hybcell.
If the last base is complementary to the amplificate, the probes are extended on the hybcell surface. Fluorescence-labelled amplificates and extended probes remain associated at high temperatures while hybridization. After a washing step the fluorescence is measured by the hyborg (qualitative and semi-quantitative results)